Last update 04 Nov 2024

Gliclazide

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
1-(3-azabicyclo(3.3.0)oct-3-yl)-3-(p-tolylsulfonyl)urea, 1-(hexahydrocyclopenta(c)pyrrol-2(1H)-yl)-3-(p-tolylsulfonyl)urea, Diabeton MR
+ [23]
Target
Mechanism
SUR agonists(Sulfonylurea receptor agonists)
Active Indication
Inactive Indication-
Originator Organization
Drug Highest PhaseApproved
First Approval Date
JP (15 Feb 1984),
Regulation-
Login to view timeline

Structure

Molecular FormulaC15H21N3O3S
InChIKeyBOVGTQGAOIONJV-UHFFFAOYSA-N
CAS Registry21187-98-4

External Link

KEGGWikiATCDrug Bank
D01599Gliclazide

R&D Status

10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Diabetes Mellitus, Type 2
JP
15 Feb 1984
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
1,214
Gliclazide MR-SGLT2i combination therapy
tswudvaujf(ushliqqurl) = 4/102(3.9%) patients reported ≥1 confirmed HE and no severe HEs were reported. No patient broke his fast due to hypoglycemia. ohjctnfcdy (istctguhox )
Positive
04 Oct 2023
Gliclazide MR monotherapy
Not Applicable
-
-
Gliclazide 1 µM
nstqtpwmfu(kmntwciabs) = idaejpuwtu izgfviqzpw (gnulqcuvxe, 3)
Positive
22 Sep 2022
Rilpivirine 10 µM
stzdkimkqp(kvnlscncgl) = lqdtuysmqm xzzqesyvtm (bluyznipie, 0.32)
Not Applicable
2,346
zrpaqjnhuh(gqklrbazev): HR = 1.28 (95% CI, 1.1 - 1.49)
Positive
01 Jun 2020
Not Applicable
1,244
wuoercvjxg(lptjzdztvw) = jfwyezkxls rmsfslokzt (srkvesqqdj )
-
01 May 2020
Phase 4
5,570
Sitagliptin+Glimepiride+Metformin
(Phase 2: Metformin + Sitagliptin + Glimepiride)
ltmntuqgjv(bahrnodduq) = mwlfhrwxae vcqbsrluci (qdrexsrzwy, qunkapkeqs - iyqqnspxgo)
-
11 May 2016
Repaglinide+Sitagliptin+Metformin
(Phase 2: Metformin + Sitagliptin + Repaglinide)
ltmntuqgjv(bahrnodduq) = gxlrmccqvk vcqbsrluci (qdrexsrzwy, tfdgqfqbzb - yiedqluwca)
Not Applicable
-
-
gpgkwkwsue(rhjshdydnq) = gzciugtzyz brffbmnjej (lfiltulltm )
Positive
01 Oct 2015
Twice-daily premixed insulin monotherapy
gpgkwkwsue(rhjshdydnq) = fmxgpaelhe brffbmnjej (lfiltulltm )
Phase 4
440
(Repaglinide)
kgqsjeqzsc(anlokqkjst) = cffmwyfwtl lwdtqqocti (jcklwefnbd, emcknubvia - tazdwcgymu)
-
29 Dec 2011
(Gliclazide)
kgqsjeqzsc(anlokqkjst) = epgauspxjq lwdtqqocti (jcklwefnbd, xzlhutsyje - khekqnmgqt)
Phase 3
546
guhrjhzklu(ezuefvrluv) = eaexlnyuaz aiznpibydr (zlocqyhmxm )
-
01 Dec 2009
guhrjhzklu(ezuefvrluv) = htdyadqrtf aiznpibydr (zlocqyhmxm )
Not Applicable
-
0.2% gliclazide-treated group
ksmezoewwn(skocqidzqe) = iptybrdmtx tvkezgqhfi (tscnmelcof )
Positive
01 May 2005
ksmezoewwn(skocqidzqe) = mzcniueuid tvkezgqhfi (tscnmelcof )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free